

ANGIODYNAMICS®

AngioDynamics to Hold Fiscal Fourth Quarter and 2004 Financial Results Conference Call on Thursday, July 29, 2004

QUEENSBURY, N.Y.--(BUSINESS WIRE)--July 22, 2004--AngioDynamics, Inc. (Nasdaq:ANGO) today announced that the company will release fourth quarter and 2004 year end results on Thursday, July 29, 2004.

Eamonn P. Hobbs, president and chief executive officer, and Joseph G. Gerardi, chief financial officer, will host an investment conference call beginning at 4:30 p.m. Eastern Time on July 29 to discuss these results and to answer questions.

To participate in the live call by telephone, please dial (888) 804-7108 from the U.S., or for international callers, please dial (706) 634-1250.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of AngioDynamic's web site at <http://investor.angiodynamics.com/>. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the Web site for 14 days. A telephone replay will be available from 7:30 p.m. Eastern Time July 29, 2004 through 11:59 p.m. Eastern Time on July 31 by dialing (888) 642-1687 (domestic) or (706) 645-9291 (international) and entering conference ID number 8933586.

About AngioDynamics

AngioDynamics, Inc. designs, develops, manufactures and markets innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. It offers a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. AngioDynamics' diversified product line includes angiographic catheters, hemodialysis catheters, PTA dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, as well as drainage products. AngioDynamics is a majority-owned subsidiary of E-Z-EM, Inc. (AMEX:EZM), a leading manufacturer of contrast agents for gastrointestinal radiology.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations.

CONTACT: AngioDynamics, Inc.
Lisa Donegan, (800) 772-6446 x370
www.AngioDynamics.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgoledetz@lhai.com)
Shayne Payne (spayne@lhai.com)
(212) 838-3777
Bruce Voss (bvoss@lhai.com)
(310) 691-7100

SOURCE: AngioDynamics, Inc.